Role of Fatty Liver Disease in Childhood Obesity

Research output: Chapter in Book/Report/Conference proceedingChapter


Nonalcoholic fatty liver disease can no longer be considered a benign entity, as the fat infiltration of the hepatic parenchyma is significantly associated with visceral adiposity, features of the metabolic risk (mainly increased risk for prediabetes and type 2 diabetes and anticipated cardiovascular disease). No matter what the mechanisms of the progression from nonalcoholic fatty liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) are, it seems that even fatty liver can be a worrisome condition, able to significantly impact health costs. It is also likely that by counteracting NAFLD, the onset of the cardiovascular disease can be delayed or reduced. The only proven therapeutic strategy for the treatment of fatty liver in overweight and obese children consists of stable lifestyle changes. So far, the prescription of medications, including insulin sensitizers and antioxidants, did not provide better results than lifestyle changes in terms of both biochemical parameters and liver histology. Other medications (i.e., orlistat or lipidlowering drugs) or medical and surgical procedures (i.e., the Roux-en-Y gastric bypass [RYGB]) may be prescribed in the presence of poor compliance to the prescription of lifestyle changes or severe metabolic abnormalities associated with overweight and obesity.

Original languageEnglish
Title of host publicationGlobal Perspectives on Childhood Obesity
PublisherElsevier Inc.
Number of pages10
ISBN (Print)9780123749956
Publication statusPublished - 2011

ASJC Scopus subject areas

  • Health Professions(all)
  • Nursing(all)


Dive into the research topics of 'Role of Fatty Liver Disease in Childhood Obesity'. Together they form a unique fingerprint.

Cite this